Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese by Liu, Jie et al.
RESEARCH ARTICLE Open Access
Association of genetic polymorphisms in the
interleukin-10 promoter with risk of prostate
cancer in Chinese
Jie Liu
1†, Bao Song
2†, Xueli Bai
3, Wenjian Liu
4, Zengjun Li
1, Jialin Wang
2, Yan Zheng
1, Zhehai Wang
1*
Abstract
Background: Recent studies identified an increased risk of prostate cancer (PCa) in Caucasian men harboring
polymorphisms of genes involved in innate immunity and inflammation. This study was designed to assess
whether single nucleotide polymorphisms in the IL-10 promoter play a role in predisposing individuals to PCa in a
Chinese population.
Methods: We genotyped three SNPs of the IL-10 promoter (-1082A/G, -819T/C and -592A/C) using polymerase
chain reaction-restriction fragment length polymorphism analysis in 262 subjects with PCa and 270 age-matched
healthy controls. Odds ratio and 95% confidence interval were determined by logistic regression for the
associations between IL-10 genotypes and haplotypes with the risk of PCa and advanced PCa grade.
Results: No significant differences in allele frequency or genotype distribution were observed for any of the IL-10
SNPs between PCa patients and control subjects. Significantly higher frequencies of -1082G, -819C and -592C allele
and GCC haplotype were observed, however, in early stage patients in comparison to advanced PCa patients (for
-1082 G, 13.9% vs 6.1%, OR = 2.48, P = 0.005; for -819 C 40.3% vs 30.8%, OR = 1.51, P = 0.043; for -512C, 40.3% vs
30.8%, OR = 1.51, P = 0.043; and for haplotype GCC 11.1%vs 5.1%, OR = 2.66, P = 0.008, respectively).
Conclusions: Our results identify that IL-10 promoter polymorphisms might not be a risk factor for PCa in Chinese
cohorts, but rather incidence of polymorphisms associates with PCa grade, suggesting that IL-10 expression may
impact PCa progression.
Background
Prostate cancer (PCa) is among the most common
malignant tumors in Western males, ranking second
only to lung cancer in cancer mortality [1]. PCa inci-
dence in Asian men is significantly lower, however, the
incidence of PCa in China has increased significantly in
recent years [2]. While age, ethnicity, diet, and geo-
graphic factors are believed to contribute to the etiology
of this disorder [3-5], genetic variations may play a role
in susceptibility to PCa [6]. Recent studies suggest that
genetic polymorphisms of genes involved in innate
immunity and chronic inflammation, including the anti-
inflammatory cytokine Interleukin-10 (IL-10), may
impact susceptibility to PCa [6].
IL-10 is produced primarily by macrophages and T
lymphocytes. It has important anti-inflammatory and
immunosuppressive activities, including the ability to
downregulate T helper 1 (Th1) cytokine and macro-
phage costimulatory molecule expression. The impact of
IL-10 on macrophage function appears to influence
blood vessel growth, as reports indicate that IL-10 may
contribute to the regulation of angiogenesis in various
cancers [7,8]. Due to its immunosuppressive and anti-
inflammatory properties, it has been hypothesized that
IL-10 contributes to tumor escape from immune surveil-
lance, thereby enhancing tumor growth. Conversely, ani-
mal and in vitro studies demonstrate a correlation
between high levels of IL-10 with smaller tumors and
reduced metastasis [9].
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late IL-10 expression. The gene encoding IL-10 is
located on chromosome 1 (1q31-1q32), and many poly-
morphisms of the IL-10 gene promoter have been
described. Examples of polymorphisms include -1082 A/
G (rs 1800896), -819 T/C (rs1800871) and -592 A/C
(rs1800872) in the proximal region, which influence the
transcription of IL-10 mRNA and the expression of IL-
10 in vitro [10-12]. In vitro stimulation of peripheral
blood lymphocytes using concanavalin A revealed that
IL-10 -1082 GG is associated with a 1.3-fold increase in
IL-10 protein production compared to the AA genotype
[13]. Similarly, the GCC haplotype exhibits significantly
higher transcriptional activity than the ATA haplotype
in a luciferase reporter system [14].
Multiple studies have investigated the association
between IL-10 expression and incidence of PCa [15-17].
Polymorphisms of the IL-10 promoter at -1082 [13-15],
-819 or -592 [16] reduce protein expression, and associ-
ate with an increased incidence of PCa in some reports
[15-18]. In contrast, genetic variation at -592, -819, or
-1082 or the promoter haplotype ATA resulted in no
association in others [19,20]. These discrepancies sug-
gest that further investigation of the association of IL-10
SNPs with PCa is warranted. Additionally, no such stu-
dies have analyzed the impact of these polymorphisms
on PCa risk in Chinese patients. Here, we report the
association of IL-10 polymorphisms with prostate cancer
risk in a Chinese population.
Methods
Study subjects
The study included 262 newly diagnosed prostate cancer
cases (aged 46-83 years) recruited from Shandong Can-
cer Hospital and Institute, Shandong Provincial Hospital
and the Affiliated Hospital of Taishan Medical Univer-
sity between March 2006 and December 2008. The diag-
nosis of prostate cancer was based on digital rectal
examination, serum Prostate specific antigen (PSA) con-
centration determination and transrectal ultrasound
guided prostate biopsy. PSA concentration of 4.0 ng/mL
was considered a cut-off value to carry out diagnostic
work-up. Adenocarcinoma of t h ep r o s t a t ew a sp a t h o l o -
gically confirmed in all the cases, and the Gleason score
(highly differentiated, score 2-5; moderately differen-
tiated, score 6-7; poorly differentiated, score 8-10) was
evaluated by pathologists working at each hospital using
the Gleason scoring system [21]. The clinical T stage of
the patients with PCa was evaluated according to the
2002 TNM staging system for cancer [22]. We defined
more aggressive and less aggressive disease based on
tumor stage and Gleason score. “Advanced prostate can-
cer” was defined as either a Gleason score >7 or clinical
T stage >T2.
270 population controls (aged 46~81 years) were
accrued from healthy volunteers who visited the three
hospitals between July 2006 and July 2008 for general
health exams. Controls were screened to ensure that
they had never been diagnosed with cancer or other ser-
ious disease. The selected controls were matched to the
cases by age (±5 years). Each subject was interviewed for
family history of prostate cancer and smoking status. All
subjects were unrelated ethnic Han Chinese. Written
informed consent was obtained from each participant.
The study was approved by the Review Boards of Shan-
dong Cancer Hospital and Institute. Each study partici-
pant provided 2 ml peripheral blood sample.
Genotyping
Genomic DNA was extracted from peripheral blood using
Qiagen DNA Isolation Kit (Qiagen GmbH, Hilden, Ger-
many). IL-10 promoter polymorphisms were identified by
PCR amplification and restriction analysis (PCR-RFLP;
Table 1). Each PCR reaction was performed in a Gen-
eAmp PCR System 9600 thermocycler (Applied Biosys-
tems, Foster, CA) at a final volume of 25 μl (containing
5 pmol of each primer, 50 ng genomic DNA, 1.5 mM
MgCl2, 5 uM dNTPs and 1 U of Taq DNA polymerase in
PCR buffer containing 10 mM Tris-HCl and 50 mM KCl).
PCR cycles used were as follows: 95°C for 5 min, 35 cycles
of denaturing at 95°C for 40 s, annealing at the indicated
temperature for 1 min, extension at 72°C for 40 s, and a
single final extension at 72°C for 10 min. The amplified
products were digested with corresponding restriction
endonucleases (New England Biolabs, MA, USA), and
separated by electrophoresis on a 10% polyacrylamide gel
stained with sliver nitrate for visualization. To confirm the
genotyping results, 10% of PCR-amplified DNA samples
were examined by DNA sequencing. Results between PCR
and DNA sequencing analysis were 100% concordant.
Statistical analysis
The SPSS statistical software package ver.13.0 (SPSS
Inc., Chicago, USA) was used for statistical analysis.
Demographic data between the study groups were com-
pared by chi-square test and by Student t-test. Each
polymorphism was tested for deviation from Hardy-
Weinberg equilibrium by comparing the observed and
expected genotype frequencies using the chi-square test.
For SNP analyses, genotype and allele frequencies of IL-
10 were compared between groups using the chi-sqare
test, and odds ratios (OR) and 95% confidence intervals
(CIs) were calculated using unconditional logistic regres-
sion with adjustment for age and smoking status. The
linkage disequilibrium of the three loci and haplotypes
of IL-10 (-1082,-819,-592) were conducted using the
SHEsis software, from the website http://analysis.bio-x.
cn/ (Bio-X Inc., Shanghai, China) [23], which uses a
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haplotypes. Additionally, the chi-sqare test was used to
perform the association of IL-10 allelic and haplotype
frequencies and the “advanced grade” among PCa
patients. P values <0.05 were considered to be statisti-
cally significant.
Results
Characteristics of PCa patients and controls
A total of 262 prostate cancer cases and 270 healthy
controls were recruited for the present study. All sub-
jects were ethnic Chinese. Table 2 shows the
demographic characteristics of the case and control
groups. The age distributions and smoking status were
similar for cases and controls. The incidence of people
with a family history of PCa was higher in the case
g r o u pt h a ni nt h ec o n t r o lg r o u p ,h o w e v e rt h ed i f f e r -
ences were not significant (5.3% vs 2.2%, P = 0.067).
The average PSA level in case patients 128.33 ± 634.21
(4.0-4165.0)ng/ml was significantly higher than in con-
trols 2.146 ± 0.954 (0.1~3.9)ng/ml (P < 0.001). Among
the PCa group, 182 (69.5%) of cases had a high serum
PSA level > 10 ng/ml; 161 (62.5%) cases were Gleason
>7; 156 (59.5%) cases were >T2 stage. According to our
Table 1 Primers, restriction enzymes and length of digested fragments of IL-10 promoter polymorphism
Polymorphism Primer sequence Annealing temperature Restriction enzyme Allele size
IL-10-1082G/A 5’-CTCGCTGCA ACCCAACTGGC-3’ 58°C MnlⅠ A:139 bp
5’-TCTTACCTATCCCTACTTCC-3’ G:106,33 bp
IL-10-819C/T 5’-TCATTCTATGTGCTGGAGATGG-3’ 59°C Mae III C:125,84 bp
5’-TGGGGGAAGTGGGTAAGAGT-3’ T:209 bp
IL-10-592C/A 5’-GTGAGCACTACCTGACTAGC-3’ 58°C RsaI C:412 bp
5’-CCTAGGTCACAGTGACGTGG-3’ A:175,237 bp
Table 2 Characteristics of PCa patients and controls
Characteristics Patients, n (%) (n = 262) Controls, n (%) (n = 270) P
Age
<50 8(3.0) 9(3.3) 0.729
50-59 18(6.9) 20(7.4)
60-69 83(31.7) 86(31.9)
70-79 123(46.9) 130(48.1)
≥80 30(11.5) 25(9.3)
Average age 70.7 ± 8.4 70.2 ± 8.5
Smoking status
Nonsmoking 102 (38.9%) 109(40.4%) 0.734
smoking 160(61.1%) 161(59.6%)
History of prostate cancer
Yes 14(5.3) 6(2.2) 0.067
No 248(94.7) 264(97.8)
PSA (ng/ml)
Average concentration 128.33 ± 634.21 2.146 ± 0.954 <0.001
≤10 80(30.5)
>10 182(69.5)
Gleason score
≤7 72(27.5)
>7 161(62.5)
missing 29(11.0)
Clinical T Stage
≤T2 93(35.5)
>T2 156(59.5)
missing 13(5.0)
Agressive status
Early stage 72(27.5)
Advanced stage 180(68.7)
missing 10(3.8)
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“advanced” cases (180) than “early stage” (72 cases)
among the PCa patients (68.7% vs. 27.5%).
IL-10 gene polymorphisms and PCa
Table 3 shows the distributions of the genotypes and
alleles of the IL-10 promoter polymorphisms. The geno-
type distributions for each SNP were consistent with
Hardy-Weinberg equilibrium (HWE). Overall, no signifi-
cant differences between PCa and control subjects were
observed. Allele analyses revealed IL-10-1082 G in 8.4%
of PCa subjects, vs. 6.1% of controls (P = 0.113). Simi-
larly, IL-10-819 C and -592 C were observed in 33.6% of
PCa subjects vs. 30.7% of controls (P = 0.309). Haplo-
type analyses were performed, and the 4 possible haplo-
type (ATA, ACC, GCC, GTA) frequencies are shown in
Table 3. Strong Linkage disequilibrium (LD) was
observed between -1082 and -819 (D’ = 0.892) and
-1082 and -592 (D’ = 0.892). Complete LD was observed
between -819 and -592 (D’ = 1.0). Major ATA haplotype
accounted for 68.1% and 64.9% of these four haplotypes
in both of the cases and the controls, respectively. There
were no significant differences in the estimated
frequencies of these haplotypes between PCa patients
and controls.
Association of IL-10 polymorphisms with PCa
aggressiveness
We next compared the incidence of IL-10 polymorph-
isms in prostate cancer patients in relation to their
advanced status. The frequency of the G allele -1082
was significantly higher in early stage PCa patients
than in advanced patients (13.9% vs. 6.1%, respectively;
OR = 2.48, 95%CI 1.31~4.70, P = 0.005). At the -819
and -592 sites, the C and C alleles were also found
more frequently in early stages patients than in
advanced PCa patients (40.3% vs. 30.8%, OR = 1.51,
95%CI 1.01~2.26, P = 0.043; Table 4). Additionally,
haplotype analysis showed that the frequency of GCC
was higher in early stage patients (11.1%, OR = 2.66,
P = 0.008) in comparison to advanced PCa patients
(5.0%). Taken together, these data identify no signifi-
cant correlation between frequency of IL-10 poly-
morphisms and incidence of PCa, however they did
reveal a correlation between frequency of polymorph-
isms and PCa stage.
Table 3 IL-10 polymorphisms and risk of PCa
Genotype/Allele/haplotype Controls n (%) PCa n (%) P Adjusted OR* (95%CI)
Genotype(-1082A/G)
AA 240(88.9) 222(84.7) 1.00
AG 27(10.0) 36(13.7) 0.141 1.50(0.87~2.57)
GG 3(1.1) 4(1.5) 0.520 1.68(0.35~8.17)
Allele
A 507(93.9) 480(91.6) 1.00
G 33(6.1) 44(8.4) 0.113 1.48(0.91~2.38)
Genotype(-819 C/T)
TT 132(48.9) 120(45.9) 1.00
TC 110(40.7) 108(41.2) 0.675 1.08(0.75~1.56)
CC 28(10.4) 34(12.9) 0.296 1.35(0.77~2.36)
Allele
T 374(69.3) 348(66.4) 1.00
C 166(30.7) 176(33.6) 0.309 1.14(0.88~1.48)
Genotype(-592 C/A)
AA 132(48.8) 120(45.9) 1.00
AC 110(40.8) 108(41.2) 0.675 1.08(0.75~1.56)
CC 28(10.4) 34(12.9) 0.296 1.35(0.77~2.36)
Allele
A 374(69.3) 348(66.4) 1.00
C 166(30.7) 176(33.6) 0.309 1.14(0.88~1.48)
Haplotype
ATA 368(68.1) 340(64.9) 1.00
ACC 139(25.7) 140(26.7) 0.551 1.13(0.86~1.47)
GTA 6(1.1) 8(1.5) 0.489 1.42(0.56~4.12)
GCC 27(5.0) 36(6.9) 0.174 1.45(0.86~2.47)
OR*, adjusted for age and smoking status
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In the present study, we analyzed the association
between 3 SNPs of the IL-10 promoter (-1082 A/G,
-819 T/C, and -592 A/C) with incidence of prostate can-
cer in a Chinese cohort. No significant differences in
allele frequency or genotype distribution for any of the
IL-10 SNPs were observed between patients with PCa
and control subjects. However, significantly higher fre-
quencies of the -1082G, -819C and -592C allele and
GCC haplotype were observed in early stage PCa
patients in comparison to advanced PCa patients.
IL-10 is a multifunctional cytokine with both immuno-
suppressive and anti-angiogenic functions, consequently
resulting in both tumor-promoting and tumor-inhibiting
properties. Multiple epidemiological studies have investi-
gated the association between the IL-10 polymorphisms
and the risk of different cancer types. Increased serum
and peritumoral IL-10 production have been reported in
many malignancies. Results with respect to PCa, how-
ever, have been inconsistent. The A allele of IL-10-1082
was reported by several groups to be positively associated
with incidence of PCa [15-17]. Similarly, the T allele at
-819 and A allele at -592 resulting in low IL-10 expres-
sion, have been associated with increased PCa risk, speci-
fically in high grade tumors [18]. In contrast, Eder et al
[19] or Michaud et al [20] report no correlation between
IL-10 expression and PCa risk/status. The cause of these
differences remains unclear, however several possibilities
exist. Discrepancies may exist due to genetic trait differ-
ences, or the existence of distinct IL-10 genetic poly-
morphisms amongst specific populations, ethnicities and
geographic regions. Furthermore, cancer is a multi-fac-
torial disease. Individual exposures to various environ-
mental factors in combination with genetic susceptibility
may have contributed to these varied results.
We observe that the frequency of the IL-10-1082G
allele in Chinese is similar to the frequencies observed
in healthy Korean [24] and Japanese [25] populations,
but significantly lower than those reported for Caucasian
populations (where the frequency of IL-10-1082G is
approximately 0.45) [18,20]. Interestingly, the frequency
of -1082A (93.9%) and ATA (68%) is higher in Chinese
populations than in Caucasians, yet the incidence of
PCa in Chinese populations is much lower than what is
observed in Caucasians. As the IL-10 -1082 A allele and
haplotype ATA are associated with increased PCa risk
in Caucasian populations, the association of these poly-
morphisms with PCa appears to be ethnically or geogra-
phically regulated. The -819T allele and -592A allele are
in complete linkage disequilibrium in the present study.
The allele ratio for -819 T/-592 A is 0.69, significantly
higher than those reported for Caucasians (where the
frequency of -819T and -592A are approximately 0.22 to
0.32) [18,20]. These data further confirm that IL-10
alleles vary significantly among ethnic groups, and war-
rant further investigation.
According to the International Agency for Research
on Cancer (IARC), the incidence of prostate cancer in
China was 1.1/10
5 person years (PY) in 1990 [26] and
1.6/10
5 PY in 2002[27]. China has the lowest incidence
of prostate cancer in the world, yet the manjority of
prostate cancers are not diagnosed until the advanced
stages of disease progression. As serum prostate-specific
antigen (PSA) screening is the only diagnostic for pros-
tate cancer used in China diagnosis may be greatly
enhanced by consideration of genetic background. Sev-
eral studies have reported that the IL-10 -1082A allele
and ATA haplotye, minor types in Caucasians but major
types in China, were associated with increased PCa risk.
These results, which suggest that the incidence of PCa
Table 4 Association of IL-10 polymorphisms with PCa aggressiveness
Allele/Haplotype Early stage (72) Advanced stage (180) P OR (95%CI)
-1082A/G
A 124(86.1) 338(93.9) 1.00
G 20(13.9) 22(6.1) 0.005* 2.48(1.31~4.70)
-819 C/T
T 86(59.7) 249(69.2) 1.00
C 58(40.3) 111(30.8) 0.043* 1.51(1.01~2.26)
-592 C/A
A 86(59.7) 249(69.2) 1.00
C 58(40.3) 111(30.8) 0.043* 1.51(1.01~2.26)
Haplotype
ATA 82(56.9) 245(68.1) 1.00
ACC 42(29.2) 93(25.8) 0.184 1.35(0.87~2.10)
GTA 4(2.8) 4(1.1) 0.128 2.99(0.73~12.2)
GCC 16(11.1) 18(5.0) 0.008* 2.66(1.30~5.45)
*P < 0.05.
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results of our study described here. Clearly, the associa-
tion of IL-10 SNPs and PCa risk and progression war-
rant future large-scale investigation throughout multiple
ethnic populations.
Here, we analyzed the association between IL-10 poly-
morphisms and PCa risks in a Chinese population. Our
study revealed that there is no association between
IL-10 SNPs and incidence of PCa, however a signifi-
cantly higher frequency of -1082G, -819C and -592C
alleles and GCC haplotype were observed in early stage
patients compared to advanced PCa patients. To the
best of our knowledge, this study is the first to assess
the association of IL-10 gene polymorphisms with PCa
for the Chinese population. Our results did not support
ar o l ef o rIL-10 SNPs in developing PCa, but as IL-10
expression alters according to cancer grade, our data
suggest that IL-10 expression may impact prostate can-
cer progression. While the precise mechanisms by
which IL-10 polymorphisms may modulate PCa progres-
sion remains known, evidence suggests that IL-10 mod-
ulates immune function, such as NK cell, T cells, and
macrophages activity, which would alter disease progres-
sion. Additionally, increasing evidence suggests a role
for IL-10 in inhibition of angiogenesis, therefore
decreases IL-10 expression would de-repress angiogenic
activity and promote cancer progression. Acknowledging
the relatively limited sample size and for the low allelic
frequencies, further studies are warranted.
Conclusions
In conclusion, Our results suggest that IL-10 promoter
polymorphisms might not be a risk factor of PCa devel-
opment but may impact PCa progression in Chinese
patients.
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